Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 13, Number 3—March 2007

Research

Matrix Protein 2 Vaccination and Protection against Influenza Viruses, Including Subtype H5N1

Stephen Mark Tompkins*1Comments to Author , Zi-Shan Zhao*, Chia-Yun Lo*, Julia A. Misplon*, Teresa Liu*, Zhiping Ye*, Robert J. Hogan†, Zhengqi Wu*, Kimberly A. Benton*, Terrence M. Tumpey‡, and Suzanne L. Epstein*
Author affiliations: *Food and Drug Administration, Bethesda, Maryland, USA; †University of Georgia, Athens, Georgia, USA; ‡Centers for Disease Control and Prevention, Atlanta, Georgia, USA;

Main Article

Figure 4

Results of matrix protein 2 (M2) vaccination and booster with DNA prime–adenovirus (Ad), showing cross-reactive antibodies. Mice (8–10 per group) were vaccinated with DNA and given an Ad booster as described in Methods. Immune serum collected 3 weeks after the booster was assayed for immunoglobulin (Ig) G reactive to various M2e peptides by ELISA, as described in Methods. Plates were coated with M2e-PR8 (panel A), M2e-FM (panel B), M2e-H5(SP-83) (panel C), or M2e-H5(HK) (panel D). OD, optical de

Figure 4. Results of matrix protein 2 (M2) vaccination and booster with DNA prime–adenovirus (Ad), showing cross-reactive antibodies. Mice (8–10 per group) were vaccinated with DNA and given an Ad booster as described in Methods. Immune serum collected 3 weeks after the booster was assayed for immunoglobulin (Ig) G reactive to various M2e peptides by ELISA, as described in Methods. Plates were coated with M2e-PR8 (panel A), M2e-FM (panel B), M2e-H5(SP-83) (panel C), or M2e-H5(HK) (panel D). OD, optical density.

Main Article

1Current affiliation: University of Georgia, Athens, Georgia, USA

TOP